Free press releases distribution network?

Agency / Source: Greystone Associates

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone Associates - Greystone Associates analyzes the market impact and potential of evolving injectable drug technologies
Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone Associates

 

PRTODAY - Newswire & PRZOOM/ - Amherst, NH, United States, 05/26/2010 - Greystone Associates analyzes the market impact and potential of evolving injectable drug technologies.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Injectable drug formulations designed to improve drug half-life and extend dosing intervals can mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs.

Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase. Already a ten billion dollar retail revenue market, the value of injectable drugs with extended dosing regimens will increase nine percent annually through 2013 as new controlled release formulations reach the market.

A new report analyzes the current market and potential for extended release injectables. The report – Sustained Release Injectables: Technologies, Targets and Therapeutics - examines the therapeutic impact of approved sustained release injectable drugs, assesses development-stage candidates, and analyzes key market segments, technology factors, demand drivers and the competitive landscape.

About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Greystone Associates

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone Associates

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
|
Contact: Mark Smith - GreystoneAssociates.org 
603-595-4340 mksmith[.]greystoneassociates.org
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone AssociatesAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From Greystone Associates / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
Sartorius Stedim Biotech and Penn State University Announce Partnership
SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-line Treatment of Adults with Intermediate or Poor Risk aRCC
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion
BASF Launches Hepaxa as First Dedicated Product in the U.S. to Help Patients Manage Non-Alcoholic Fatty Liver Disease
Legend Biotech Announces Closing of Global Strategic LCAR-B38M Car-T Cell Immunotherapy Collaboration with Janssen
Arix Bioscience and Ipsen Sign A Strategic Agreement to Develop and Commercialise Innovative Therapies
Ipsen Announces Eight Oral Presentations from its Neurosciences Portfolio At the 10th World Congress for Neurorehabilitation (WCNR)

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  JobsWare.com

Visit  NAKIVO, Inc.

Visit  E-MetroTel Global, Inc.





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)